Invacare Corporation

Invacare said Q3 consolidated reported net sales declined across all main product categories, but did not give a total revenue figure on the call. Gross margin declined due to higher input costs, production stoppages, and unfavorable FX, with 510 basis points of the margin impact tied to an $8.7 million write-down of inventory and purchase obligations related to the respiratory exit. Operating loss increased and adjusted EBITDA decreased, and free cash flow usage was $20.5 million. On a sequential basis, reported net sales declined 9.8% and constant-currency SG&A expense fell $3.3 million. For Q4, the company expects sequential constant-currency net sales growth and sequential adjusted EBITDA improvement, and Europe is on pace for sequential constant-currency sales improvement and positive adjusted EBITDA for the quarter.

Geoff Purtill framed the quarter as part of a broader turnaround, saying the company has been taking a hard look at every part of the business and is making decisive actions to return to profitability. He emphasized that lifestyle and mobility & seating are the core categories, citing stronger demand and open orders, while respiratory no longer meets minimum profitability targets because of excess supply, lower COVID demand, and higher input costs. His tone was confident and action-oriented, with repeated references to optimization, simplification, and shareholder value.

Kathy Leneghan tied the quarter's weakness to supply chain constraints, component shortages, FX pressure, and the respiratory discontinuation charges. She highlighted that approximately 60% of revenue is earned outside the U.S., so a stronger dollar materially hurt reported sales, and she noted Europe's year-to-date constant-currency growth despite the Q3 anomaly. She also said Q4 should improve sequentially as materials flow improves, gross profit benefits from pricing actions and better execution, and restructuring actions help costs, though she warned of additional North America restructuring charges.

Analysts asked whether Europe and the rest of the world could be separated or potentially sold, and management said the businesses have some overlap but are fairly separate, with possible buyer interest in Europe, while also calling Europe a very healthy business. Questions also focused on why U.S. seating and mobility has struggled; Geoff said reimbursement dynamics, supply chain issues, and the lack of a global portfolio have limited performance, but he sees room for growth. On supply chain and possible share loss, management said the issues are industry-wide, electronics remain difficult, freight is easing, and portfolio complexity is a challenge for Invacare, though they did not rule out competitive pressures.